secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELITE PHARMACEUTICALS INC /NV/ (ELTP)
CIK:        0001053369
Form:       8-K
Filed at:   2022-11-15T23:59:59+00:00
Accession:  0001493152-22-032436
Event type: earnings
Sentiment:  positive
Materiality: 0.50
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elite Pharmaceuticals Q2 FY2023: Revenue $16.3M (+4% YoY), Net Income $1.82M
----------------------------------------------------------------------------

- Consolidated six-month revenue $16.3M, up 4% YoY vs prior year.
- Operating profit $2.1M; net income $1.82M for the six-month period.
- Revenue growth attributed to generic immediate-release and extended-release Adderall.
- Conference call on Nov 15, 2022 at 11:30 AM EST; dial-in 1-800-346-7359.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053369/000149315222032436/0001493152-22-032436-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053369/000149315222032436/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-032436

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer